Sanofi
SNY | NASDAQ
$44.34
+$1.21 (+2.81%)
At close: Oct 30, 2026, 4:00 PM ET
$44.73
+$0.39 (+0.88%)
Pre-market:
Nov 2, 2026, 4:11 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 46.72B | 44.29B | 41.62B | 40.56B | 39.18B | 37.37B |
Cost of Revenue | 13.05B | 13.21B | 12.63B | 11.88B | 12.26B | 12.16B |
Gross Profit | 33.67B | 31.08B | 28.99B | 28.68B | 26.92B | 25.21B |
Operating Income | 9.6B | 7.25B | 6.96B | 10.16B | 8.13B | 14.11B |
Interest Income | 331M | 457.53M | 530.5M | 168.96M | 3.13M | 34.43M |
Pretax Income | 6.02B | 6.76B | 6.12B | 9.99B | 7.84B | 14.14B |
Net Income | 7.81B | 5.56B | 5.4B | 8.37B | 6.22B | 12.29B |
Selling & General & Admin | 10.24B | 9.18B | 8.93B | 8.74B | 9.56B | 9.39B |
Research & Development | 7.84B | 7.39B | 6.51B | 6.5B | 5.69B | 5.53B |
Other Expenses | 5.99B | 7.25B | 6.59B | 3.28B | 3.55B | -3.82B |
Operating Expenses | 24.07B | 23.83B | 22.03B | 18.52B | 18.79B | 11.1B |
Interest Expense | 626M | 622.58M | 512.82M | 384.8M | 377.37M | 430.84M |
Selling & Marketing Expenses | 699M | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 37.12B | 37.03B | 34.66B | 30.4B | 31.05B | 23.26B |
Income Tax Expense | 1.04B | 1.2B | 1.02B | 1.91B | 1.56B | 1.81B |
Shares Outstanding (Basic) | 2.44B | 2.5B | 2.5B | 2.5B | 2.51B | 2.51B |
Shares Outstanding (Diluted) | 2.44B | 2.5B | 2.51B | 2.5B | 2.51B | 2.51B |
EPS (Basic) | 3.20 | 2.19 | 2.15 | 3.19 | 2.49 | 4.91 |
EPS (Diluted) | 3.20 | 2.19 | 2.15 | 3.18 | 2.49 | 4.91 |
EBITDA | 12.48B | 11.03B | 11.39B | 13.51B | 11.54B | 17.88B |
EBIT | 6.8B | 7.45B | 6.96B | 10.4B | 8.19B | 14.21B |
Depreciation & Amortization | 5.68B | 3.59B | 4.43B | 3.11B | 3.35B | 3.67B |
Add to Watchlist
Select watchlists to add or remove SNY